Kenneth Hillan's Email & Phone

Chief Medical Officer Dr. Hillan joins Achaogen as Chief Medical Officer, bringing deep experience in both pathology and strategic global drug development. Most recently, he served as Senior Vice President and Head of Roche Product Development, Asia Pacific, where he was responsible for the overall drug development strategy in the region. Prior to that, he held a variety of positions at Genentech (acquired by Roche in 2009) including Senior Vice President Clinical Development, Inflammation, Vice President Research Operations and Pathology, Vice President, Development Sciences, and Vice President Immunology, Tissue Growth and Repair (ITGR). While there, he also served in executive leadership roles as Chair, Roche: Chugai Development Committee and Member, Roche: Chugai Joint Commercial Committee, Head, Roche Inflammation Disease Biology Leadership Team (Research through Commercial), Member, Roche Personalized Healthcare Steering Committee, Co-Chair, Genentech's Late-Stage Portfolio Committee, Executive Sponsor and Chair, Development Review Committee, Member, Genentech Research Review Committee, Member, Genentech Healthcare Compliance Committee, and Member, Genentech Product Safety Committee. Dr. Hillan has also authored dozens of scientific publications and is a named inventor on almost 50 issued patents. He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, is a Fellow of the Royal College of Surgeons (FRCS), and a Fellow of the Royal College of Pathologists (FRCPath). He also serves as Honorary Professor of Molecular and Therapeutic Pathology at the University of Leeds.